



[Go to Product page](#)

Datasheet for ABIN7317551 Factor VII Protein (His tag)

Overview

Quantity:	20 µg
Target:	Factor VII (F7)
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This Factor VII protein is labelled with His tag.

Product Details

Purpose:	Recombinant Human Coagulation Factor VII/F7 Protein (His Tag)
Sequence:	Met 1-Pro 444
Characteristics:	A DNA sequence encoding the human F7 isoform B (P08709-2) (Met 1-Pro 444) was expressed, fused with a polyhistidine tag at the C-terminus.
Purity:	> 95 % as determined by reducing SDS-PAGE.
Endotoxin Level:	< 1.0 EU per µg as determined by the LAL method.

Target Details

Target:	Factor VII (F7)
Alternative Name:	Coagulation Factor VII/F7 (F7 Products)
Background:	Background: Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII

Target Details

(FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.

Synonym: Coagulation factor 7, Coagulation factor VII, SPCA

Molecular Weight: 46.5 kDa

Pathways: [Response to Growth Hormone Stimulus, Platelet-derived growth Factor Receptor Signaling](#)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C, -20 °C, -80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.